The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1NUGA9     N-[[10-[(Z)-(4,5-dihydro-1H- imidazol-2...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Bisantrene


High impact information on Bisantrene


Chemical compound and disease context of Bisantrene


Biological context of Bisantrene


Anatomical context of Bisantrene


Associations of Bisantrene with other chemical compounds


Gene context of Bisantrene


Analytical, diagnostic and therapeutic context of Bisantrene


  1. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. Cowan, J.D., Neidhart, J., McClure, S., Coltman, C.A., Gumbart, C., Martino, S., Hutchins, L.F., Stephens, R.L., Vaughan, C.B., Osborne, C.K. J. Natl. Cancer Inst. (1991) [Pubmed]
  2. Activation of tumor-cytostatic macrophages with the antitumor agent 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazole-2-yl)hydrazone] dihydrochloride (bisantrene). Wang, B.S., Lumanglas, A.L., Ruszala-Mallon, V.M., Durr, F.E. Cancer Res. (1984) [Pubmed]
  3. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay. Alberts, D.S., Mackel, C., Pocelinko, R., Salmon, S.E. Cancer Res. (1982) [Pubmed]
  4. Immunotherapy of a murine lymphoma by adoptive transfer of syngeneic macrophages activated with bisantrene. Wang, B.S., Lumanglas, A.L., Durr, F.E. Cancer Res. (1986) [Pubmed]
  5. Human myeloma in vitro colony growth: interrelationships between drug sensitivity, cell kinetics, and patient survival duration. Durie, B.G., Young, L.A., Salmon, S.E. Blood (1983) [Pubmed]
  6. Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Dalton, W.S., Cress, A.E., Alberts, D.S., Trent, J.M. Cancer Res. (1988) [Pubmed]
  7. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis. Powis, G., Kovach, J.S. Cancer Res. (1983) [Pubmed]
  8. Bisantrene, an active new drug in the treatment of metastatic breast cancer. Yap, H.Y., Yap, B.S., Blumenschein, G.R., Barnes, B.C., Schell, F.C., Bodey, G.P. Cancer Res. (1983) [Pubmed]
  9. Quantitation of differential sensitivity of normal marrow myeloid progenitor cells to anthracene derivatives. Bron, D., Dodion, P., Rozencweig, M., Delforge, A., Mattelaer, M.A., Kenis, Y., Stryckmans, P. Investigational new drugs. (1986) [Pubmed]
  10. Chemosensitivities of human clonogenic breast tumor cells. Hug, V., Thames, H., Hortobagyi, G., Finders, M. European journal of cancer & clinical oncology. (1986) [Pubmed]
  11. Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity. Aksentijevich, I., Cardarelli, C.O., Pastan, I., Gottesman, M.M. Clin. Cancer Res. (1996) [Pubmed]
  12. N-phosphoryl derivatives of bisantrene. Antitumor prodrugs with enhanced solubility and reduced potential for toxicity. Murdock, K.C., Lee, V.J., Citarella, R.V., Durr, F.E., Nicolau, G., Kohlbrenner, M. J. Med. Chem. (1993) [Pubmed]
  13. Mitoxantrone and bisantrene inhibition of platelet aggregation and prostaglandin E2 production in vitro. Frank, P., Novak, R.F. Biochem. Pharmacol. (1985) [Pubmed]
  14. Light, fluorescent, and electron microscopic analysis of cultured breast tumor cells (T-47D) treated with 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride. Tseng, M.T., Safa, A.R. Cancer Res. (1983) [Pubmed]
  15. New antitumor agents containing the anthracene nucleus. Wunz, T.P., Dorr, R.T., Alberts, D.S., Tunget, C.L., Einspahr, J., Milton, S., Remers, W.A. J. Med. Chem. (1987) [Pubmed]
  16. Bisantrene solubility and skin toxicity studies: efficacy of sodium bicarbonate as a local ulceration antidote. Dorr, R.T., Peng, Y.M., Alberts, D.S. Investigational new drugs. (1984) [Pubmed]
  17. Improved high-performance liquid chromatography of the new antineoplastic agents bisantrene and mitoxantrone. Peng, Y.M., Ormberg, D., Alberts, D.S., Davis, T.P. J. Chromatogr. (1982) [Pubmed]
  18. Clinical pharmacokinetics of 9, 10-anthracenedicarboxaldehyde-bis [(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride. Lu, K., Savaraj, N., Yap, B.S., Feun, L.G., Umsawasdi, T., Loo, T.L. Cancer Chemother. Pharmacol. (1986) [Pubmed]
  19. Regional targeting of bisantrene by directed intravascular precipitation. Kovach, J.S., Buck, M., Tsukamoto, T., Odegaard, A., Lieber, M.M. Cancer Chemother. Pharmacol. (1985) [Pubmed]
  20. In vivo and in vitro metabolism of the new anticancer drug bisantrene. Peng, Y.M., Alberts, D.S., Davis, T.P. Cancer Chemother. Pharmacol. (1985) [Pubmed]
  21. P-glycoprotein mediates profound resistance to bisantrene. Zhang, X.P., Ritke, M.K., Yalowich, J.C., Slovak, M.L., Ho, J.P., Collins, K.I., Annable, T., Arceci, R.J., Durr, F.E., Greenberger, L.M. Oncol. Res. (1994) [Pubmed]
  22. Phase II trial of bisantrene in hepatocellular carcinoma: a Southwest Oncology Group Study. Brown, T.D., Fleming, T.R., Shildt, R.A., Cowan, J.D. Cancer treatment reports. (1987) [Pubmed]
  23. DNA binding by antitumor anthracene derivatives. Wunz, T.P., Craven, M.T., Karol, M.D., Hill, G.C., Remers, W.A. J. Med. Chem. (1990) [Pubmed]
  24. Phase I clinical and pharmacokinetic study of bisantrene in refractory pediatric solid tumors. Pratt, C.B., Sinkule, J.A., Etcubanas, E., Douglass, E.C., Crom, D.B., Choi, K., Avery, L. Investigational new drugs. (1986) [Pubmed]
WikiGenes - Universities